

DIGNITANA

Clinically superior scalp cooling

AUGUST 22 • 2024



Q2 24

Advancing forward with clear vision

QUARTERLY REPORT

Advancing forward with clear vision

Financial highlights Q2 2024

- Net Sales amounted to 21.8 MSEK (21.1), an increase of 4 percent over the same quarter in 2023.
- Operating Result amounted to -11.0 MSEK (-4.7).
- Net Result after financial items amounted to -11.5 MSEK (-4.7).
- EBITDA for the second quarter were negative at -7.0 MSEK (-0.9).
- Earnings per share were -0.14 SEK (-0.07).
- Cash Balance amounted to 7.0 MSEK (5.4).
- Average Daily Treatment Revenue (ADTR)* was 223 TSEK (241) in the quarter.

” *I have and will continue to recommend DigniCap because it works and significantly reduces hair loss.*

My friends and family were pleasantly surprised that I kept most of my hair.”

- Lori, DigniCap patient

Read Lori's story on page 8

Significant events during the period

- Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.
- In May Dignitana published the Annual Report for 2023.
- Dignitana's Annual General Meeting was held on 23 May 2024, electing Fredrik Lindgren and Dr. Hope Rugo as new Directors.
- Fredrik Jonsson was appointed as CEO beginning 1 May 2024 following the resignation of Catarina Löwenadler.
- Dignitana Board Member William Cronin resigned.

Business highlights during the period

- Dignitana signed a multi-year Distribution Agreement for Konica Minolta to be the exclusive provider of The DigniCap Scalp Cooling System in Japan.
- Dignitana participated in the Annual Congress of the Oncology Nursing Society in Washington, D.C.

Key Figures

DIGNITANA GROUP	Q2 2024	Q2 2023	Q1-Q2 2024	Q1-Q2 2023	FY 2023
Net sales, TSEK	21,844	21,089	43,009	42,578	86,063
Total revenues, TSEK	22,046	23,159	43,334	44,764	89,025
Net profit after financial items, TSEK	-11,454	-4,662	-16,510	-8,600	-17,228
Cash and bank balances, TSEK	6,977	5,423	6,977	5,423	6,027
Earnings per share, SEK	-0.14	-0.07	-0.22	-0.12	-0.25
Average Daily Treatment revenue, TSEK	223	241	232	242	239

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA'S VISION IS TO ENSURE THAT CANCER PATIENTS CAN MAINTAIN DIGNITY AND QUALITY OF LIFE DURING AND AFTER CANCER TREATMENT.

Advancing forward with clear vision

Dignity is at the heart of all that we do. More than the root of our company name, in my first four months at Dignitana I have been pleased to see the embodiment of dignity in many ways: preserving identity for patients as they go through cancer treatment, growing relationships with oncology leaders, and strengthening alliances with experts in healthcare delivery. These core activities are advancing our vision to ensure that every single cancer patient can maintain dignity and quality of life during and after cancer treatment. Nearly 20,000 patients in our primary U.S. market have benefitted from DigniCap since we received FDA clearance in 2015. Globally, thousands more cancer patients each year maintain their dignity, privacy and a sense of control during cancer treatment thanks to DigniCap. But there is much more work for us to do.

Since joining Dignitana in May I have seen the business from many sides, working with our team members across the U.S. and Sweden, and getting to know some of our customers, partners, investors, and the scalp cooling market. There is no doubt that we have an opportunity for extraordinary growth, and we are diligently working to capitalize on that potential by focusing on strategic priorities, targeted growth and profitability.

Most of our resources are directed to supporting the primary US market, and although revenue in the U.S. was flat during this second period year over year, we are seeing acceleration in U.S. sales as we go into the third period. In response to the evolving market, we are expanding our portfolio of business models to address a variety of customer needs.

I am pleased to see that several of our large providers have recently expanded their locations that offer DigniCap. This is positive growth and a true sign of customer satisfaction. In addition, we are consistently adding new customers each month, and see that pace accelerating going into the third period. The focus of our sales and account management teams now is to optimize DigniCap usage where devices are deployed and continue to provide the exemplary customer service that Dignitana is known for to ensure the optimal clinical outcome. This differentiator is key as we face increased competition in the market, and it is noteworthy that the addition of new competitors also provides validation of the viability of scalp cooling and the potential for growth of this treatment.

We continue to advance reimbursement efforts in the U.S. so that patients have improved access and affordability through their insurance coverage. We have made great strides in this area, especially over the past 12 months, but it is a lengthy process to gain coverage for new medical technology. We are working to establish scalp cooling as standard of care which will facilitate universal reimbursement for all insured patients. This period we have seen positive developments in this effort, as some healthcare providers are now consistently being reimbursed for DigniCap treatments. In terms of sales, provider interest in reimbursement is growing and our Buy and Bill model has been adopted at several additional locations going into the third period.

This period we saw an increase of 4 percent in net sales, boosted by strong device sales in Europe. As we continue to expand globally, well-established distributors and partners play a key role in the business. Our investment in channel development and distributor training in the first period is now paying off and we are pleased to see sales results from these activities.

In second quarter Dignitana signed a new distribution agreement with technology market leader Konica Minolta to be the exclusive provider of DigniCap in Japan, and their initial order shipped shortly after the close of the period. The expansion of DigniCap Delta into Japan is a significant development for the Company, and we are honored to partner with Konica Minolta to respond to high demand for our advanced technology in the competitive Japanese market.

This October we will celebrate the 28th anniversary of the original patent for DigniCap filed by Swedish Oncology nurse Yvonne Olofsson. Since that time the product and the company have seen many changes. Today's technology provides clinical results far more effective than Yvonne and her engineer partner John Kern might have ever imagined. But what has not changed is that initial dream of helping patients, making their life better during a difficult time, and preserving a patient's dignity by protecting their hair. Some of you have supported Dignitana for many years. You share the vision of helping patients and you see the opportunity before us. We are well on our way thanks to your support, and I truly believe it will be a rewarding journey for all.



A handwritten signature in blue ink, which appears to read 'Fredrik Jonsson'. The signature is fluid and cursive.

Fredrik Jonsson, CEO
Dignitana AB

Dignitana through the years



32 countries
260+ centers in US

- 1970s** ● Patients worldwide begin manual scalp cooling with ice packs
- 1996** ● Swedish nurse Yvonne Olofsson invents DigniCap scalp cooling device
- 2001** ● DigniCap C2 launched in Sweden
- 2009** ● DigniCap C3 launched in Europe, Australia & Latin America
- 2015** ● **June**- DigniCap Pivotal Trial presented at ASCO
December- FDA clearance in US for female breast cancer patients using DigniCap
- 2017** ● **February**- JAMA publishes pivotal trial
July- FDA clearance expanded for DigniCap use by men and women with all solid tumors
- 2019** ● **June**- DigniCap Delta FDA clearance
March- DigniCap Delta CE Mark
- 2021** ● **March**- NCCN® treatment recommendations for Breast, Ovarian and other Gyn cancers
July- CPT Codes for scalp cooling issued by AMA
September- Cancer Australia adds scalp cooling to Guidance for Breast cancer
October- ESMO adds scalp cooling as a category IIB recommendation for European patients
- 2022** ● **January**- Medicare rate assignment
- 2023** ● **November**- Palmetto MAC Local Coverage Determination for 7 states in US
- 2024** ● **February**- Konica Minolta signed as exclusive distributor for Japan
- Today** ● DigniCap available in over 32 countries and 260+ centers in US

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid


tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta and the technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year.

Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.

Business model

The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables. In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. Dignitana offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more standard, we

are transitioning providers to this model that is widely used in healthcare. Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Since 2021 Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the introduction of CPT® codes for scalp cooling, a 2022 rate assignment from the Centers for Medicare & Medicaid Services (CMS), and a Local Coverage Determination (LCD) from the

Palmetto Medicare Administrative Contractor (MAC) which administers Medicare benefits in seven states in the southeastern United States. This provides a pathway for successful reimbursement of Medicare claims for patients in the seven- state service area. This is the first such LCD and further advances support for health care providers to receive reimbursement to administer FDA-cleared scalp cooling therapy.

Dignitana continues to work with commercial payers, Medicare and other MACs to advance reimbursement of scalp cooling and improve accessibility and affordability for patients.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 20 million incidences of cancer diagnosed annually, with 2 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in

the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 311,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10 percent of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



Before chemo



During chemo

”

It was divine timing that I inadvertently learned about scalp cooling on social media. Immediately I knew that I wanted to try it! A spark of hope ignited in me, eager to prevent cancer from taking one more thing away from me.

- Martha, Colorado



After chemo

DigniCap was a wonderful investment that allowed me to keep most of my hair.

My oncologist provided information about DigniCap. I have short, coiled hair and I am unable to wear wigs or hair coverings due to scalp sensitivity. After reviewing the DigniCap information, I felt more comfortable about undergoing chemotherapy.

My scalp cooling experience was pleasant. Reading and understanding the cap placement was beneficial. With the assistance of nurses who have worked with the cooling cap, we were able to position the cap to obtain maximum connectivity with my scalp. The nurses also help you understand the “thawing” process after the completion of the infusions.

I documented my hair loss throughout the process. I would estimate that I lost a total of 30-35 percent of my hair while using the DigniCap. In retrospect, I am certain I would have lost most, if not all of my hair had I not used the DigniCap. It has been 7 months since my last infusion. My hair is growing back and getting thicker every day.

I will continue to recommend DigniCap because it works and significantly reduces hair loss.

My friends and family were pleasantly surprised that I kept most of my hair. As a woman of color, I did not see many examples of women with my hair style and texture using scalp cooling. DigniCap was a wonderful investment that allowed me to keep most of my hair. A foundation subsidy provided made it affordable, especially when the medical bills were piling up.



Lori | Georgia

Age: 58

Diagnosis: Triple-negative Breast Cancer, Stage I

Chemotherapy Regimen: Taxotere & Carboplatin

Total Treatments: 4


Infusion Center: Emory Winship Cancer Institute

2 months after chemo

During chemo



Last chemo day



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per-treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the second quarter 2024 net sales amounted to 21,844 TSEK (21,089), an increase over the same period 2023 by 755 TSEK representing 4 percent. The main market in the U.S. showed a flat trend Q2 2023 vs Q2 2024, while we saw increased revenue from the European market year over year.

Dignitana operates by two business models: in the U.S. DigniCap systems are leased to health care providers. The Company generates revenue from leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenue is generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements as well as the sale of patient consumables.

The U.S. is the driver in placing DigniCap Delta on the market using the leasing business model. To facilitate a good usage of the assets, the Company focuses on reallocating less utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients with less investment and cost, improve patient outcomes, and thereby achieve higher growth. Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In Q2 2024 net exchange rate effects amounted to -42 TSEK (97).

Operating Expenses and Operating Result

Operating expenses, including Personnel expenses but excluding depreciation, amortization and COGS, increased during the second quarter compared to the same period last year by 5,137 TSEK and amounted to -22,085 TSEK (-16,948). The main reasons for the deviation are severance cost at 3.7 MSEK in the parent company and write offs for bad debt at 490 TSEK in US. Depreciation and amortization in the Group amounted to -4,012 TSEK (-3,747) for the second quarter. Gross Margin increased to 68 percent in Q2 compared to 66 percent same period in 2023, despite a 600 TSEK burden in Q2 2024 for inventory write down of obsolete goods under Cost of Goods Sold.

The operating result after depreciation for the Group for the second quarter 2024 was -11,023 TSEK (-4,657). Thereby EBITDA for the quarter is negative at -7,011 TSEK (910).

Financial net

The financial net was -431 TSEK (-5) in Q2, mainly affected by debt-related interest and exchange effect on loans.

Employees

At the close of the period the Company had 29 (27) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -3,524 TSEK (-3,099). Total cash flow for the period was 4,149 TSEK (-6,453).

Cash and cash equivalents at the end of the quarter amounted to 6,977 TSEK (5,423). During the second quarter the company continued to build up inventory to secure availability and shorter lead time. The right Issue carried out in Q2 added 9.7 MSEK in net cash in April. Total amount of the right Issue was 19.1 MSEK, issue costs was 0.8 MSEK and a debt of 5.6 MSEK to the main owner Agartha was converted to shares and 3.0 MSEK in bridge loan obtained during Q1 were repaid.

The Board and Management are continuously monitoring the financial position of the Company and actively working to secure cash flow. The Board and Management are of the opinion that current business plans, in conjunction with various available options for credit facilities, are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 1,430 TSEK (1,423) in the second quarter, mainly in tangible assets.

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap June 28	122 MSEK
Number of shareholders, approximately	2,140
Share price June 28	1.51 SEK
Number of shares traded during the quarter	3,375,263
Number of shares outstanding December 30	80,541,891
Registered share capital	8,054,189 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and at the general meeting in May 2023 a decision was taken to issue a maximum of 1,800,000 employee warrants to key employees of the Company. The period for the employee stock warrants runs from June 2023 to June 2026.

Largest Shareholders

28 JUNE 2024	HOLDINGS	PERCENT
AGARTHA AB	24,000,000	29.80%
SWEDBANK ROBUR MICROCAP	6,188,571	7.68%
AVANZA PENSION	5,827,414	7.24%
UBS FNANCIAL SERVICES INC	4,189,739	5.20%
HANDELSBANKEN MICROCAP SVERIGE	3,852,542	4.78%
LQM LUNDIA AB	2,631,578	3.27%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA	2,603,099	3.23%
MAGBALEO	1,856,489	2.30%
FE SMÅBOLAG SVERIGE	1,796,911	2.23%
TECHNOVOBIS AB	1,790,593	2.22%
TOTAL	54,736,936	67.96%
OTHER SHAREHOLDERS	25,804,955	32.04%
TOTAL	80,541,891	100.00%

Source: Euroclear



Before chemo



During chemo

”

I am so grateful for DigniCap. It was one of the best decisions I was able to make for myself during that time.

- Ali, Connecticut



After chemo

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment.

methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to pandemics

The outbreak of Covid-19 and the resulting restrictions have, for a long time to come, changed the conditions of most healthcare providers worldwide. The heavy workload in healthcare created a large staff turnover and forced new priorities and new work processes for both healthcare providers and suppliers, while the need for training increased. Together with the risks of new pandemic outbreaks and subsequent restrictions, this forces medical technology suppliers to be more flexible in their marketing and in their communication with customers. As an example of this, Dignitana has developed a portal through which patients and caregivers can receive training and information about the company's products and services digitally.

Risks related to military conflicts in the outside world

The company's assessment is that the ongoing military conflicts in Ukraine and Gaza do not have any significant direct effect on the operations. Indirect effects such as increases in energy and transportation costs, increased lead times on components and general cost increases may have some impact on the operations but are deemed to be manageable. If the conflicts spread to more territories, this assessment could change. U.S. is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2023 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2023.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2023 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>
This Interim Report has not been reviewed by the Group's Auditor.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 22 August 2024

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

Lina Karlsson
Board member

Richard Dilorio
Board member

Fredrik Lindgren
Board member

Hope S Rugo, MD
Board member

Income Statement- Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2024	Q2 2023	Q1-Q2 2024	Q1-Q2 2023	Full year 2023
Operating Income					
Net sales	21,844	21,089	43,009	42,578	86,063
Capitalized work for own account	0	0	0	0	0
Other operating income	202	2,070	325	2,186	2,962
Total Operating Income	22,046	23,159	43,334	44,764	89,025
Operating expense					
Goods for Resale	-6,972	-7,121	-13,161	-13,921	-27,092
Operating expense	-8,403	-7,010	-14,701	-12,797	-24,985
Personnel expense	-13,440	-9,681	-22,982	-18,454	-35,988
Depreciation and amortization of tangible and intangible assets	-4,012	-3,747	-7,878	-7,429	-15,112
Other operating expenses	-242	-257	-588	-318	-874
	-33,069	-27,816	-59,310	-52,919	-104,051
Operating profit (loss)	-11,023	-4,657	-15,976	-8,155	-15,026
Result from financial investments					
Other Interest income and similar items	334	572	880	583	1,109
Interest expenses and similar items	-765	-577	-1,414	-1,028	-3,311
	-431	-5	-534	-445	-2,202
Profit after financial items	-11,454	-4,662	-16,510	-8,600	-17,228
Profit before tax	-11,454	-4,662	-16,510	-8,600	-17,228
Tax on profit for the period	0		0	0	-135
Results for the Period	-11,454	-4,662	-16,510	-8,600	-17,363
Average number of shares	79,435,546	70,474,155	74,923,983	70,474,155	70,474,155
Earnings per share, SEK	-0.14	-0.07	-0.22	-0.12	-0.25

Balance Sheet- Dignitana Group, TSEK

DIGNITANA GROUP	2024-06-30	2023-06-30	2023-12-31
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	309	4,861	2,584
	309	4,861	2,584
Tangible assets			
Equipment, tools and installations	129	171	140
Machinery and other technical facilities	29	46	37
Leasing machines	17,893	24,890	19,849
	18,051	25,107	20,026
Financial assets			
Other long term receivables	527	292	409
	527	292	409
Total Fixed Assets	18,887	30,260	23,019
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	14,136	4,960	7,413
	14,136	4,960	7,413
Current Receivables			
Accounts Receivable	5,157	6,233	4,915
Current Tax Assets	0	0	0
Other Current Receivables	656	658	422
Prepaid expenses and accrued income	2,629	3,307	3,035
	8,442	10,198	8,372
Cash and Bank Balances	6,977	5,423	6,027
Total Current Assets	29,555	20,581	21,812
Total Assets	48,442	50,841	44,831
EQUITY AND LIABILITIES			
Equity			
Ongoing new issue	8,054	7,047	7,047
Other contributed capital	264,125	246,550	246,550
Other equity including profit for the year	-262,392	-236,881	-246,333
Total Equity	9,787	16,716	7,264
Provisions			
Other provisions for pensions and similar obligations	527	292	409
Other provisions	3,684	0	0
	4,211	292	409
Long Term Liabilities			
Other long term liabilities	4,803	5,493	6,077
Total Long Term Liabilities	4,803	5,493	6,077
Current Liabilities			
Liabilities to credit institutions	10,442	11,516	13,027
Accounts payable	11,663	3,895	6,065
Other current liabilities	1,823	6,401	6,598
Accrued expenses and deferred income	5,713	6,528	5,391
Total current liabilities	29,641	28,340	31,081
Total liabilities	34,444	33,833	37,158
Total Equity and Liabilities	48,442	50,841	44,831

Consolidated Statement of Changes in Equity

- Dignitana Group, TSEK

DIGNITANA GROUP	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2023	7,047	245,866	-228,663	24,250
Net loss for the period			-8,600	-8,600
Share warrants		684		684
Change in translation difference relating to subsidiaries			382	382
Closing equity on 6/30/2023	7,047	246,550	-236,881	16,716
Net loss for the period			-8,763	-8,763
Share warrants				0
Change in translation difference relating to subsidiaries			-689	-689
Closing equity on 12/31/2023	7,047	246,550	-246,333	7,264
Net loss for the period			-16,510	-16,510
New share issue	1,007	18,122		19,129
Issue costs		-547		-547
Change in translation difference relating to subsidiaries			451	451
Closing equity on 6/30/2024	8,054	264,125	-262,392	9,787

Statement of Cash Flows- Dignitana Group, TSEK

DIGNITANA GROUP	Q2 2024	Q2 2023	Q1-Q2 2024	Q1-Q2 2023	Full year 2023
Operating activities					
Profit after financial investments	-11,454	-4,662	-16,510	-8,600	-17,228
Adjustments for items not affecting cash flows, etc	8,815	4,544	12,923	8,319	16,835
Tax paid	0	0	0	-16	-16
Cash flow from operating activities before changes in working capital	-2,639	-118	-3,587	-297	-409
Cash flow from changes in working capital					
Change in inventories	-3,594	-648	-6,541	-797	-3,549
Change in other current receivables	-16	330	-231	273	1,407
Change in other current liabilities	2,725	-2,663	6,249	-4,257	-3,193
Cash flows from operating activities	-3,524	-3,099	-4,110	-5,078	-5,744
Investing activities					
Investments in intangible assets	0	0	0	0	0
Proceeds from sale of intangible assets	0	0	0	0	0
Investments in tangible assets	-1,382	-2,312	-3,469	-3,070	-4,597
Proceeds from sale of tangible assets	0	948	130	948	1,034
Investments in other financial fixed assets	-48	-59	-118	-117	-233
Cash flows from investing activities	-1,430	-1,423	-3,457	-2,239	-3,796
Financing activities					
New share issue	13,564	0	13,564	0	0
Issue expenses	-477	0	-547	0	0
Options issued	0	684	0	684	684
New loans	3,054	32	6,054	8,092	22,855
Repaid loans	-7,038	-2,647	-10,703	-5,006	-16,500
Cash flow from financial activities	9,103	-1,931	8,368	3,770	7,039
Cash flow for the period	4,149	-6,453	801	-3,547	-2,501
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	2,839	11,726	6,027	8,869	8,869
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	-11	150	149	101	-341
Cash and cash equivalents at end of period	6,977	5,423	6,977	5,423	6,027

Income Statement- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q2 2024	Q2 2023	Q1-Q2 2024	Q1-Q2 2023	Full year 2023
Operating Income					
Net sales	5,774	4,104	9,943	7,559	14,290
Capitalized work for own account	0	0	0	0	0
Other operating income	202	2,001	296	2,117	2,870
Total Operating Income	5,976	6,105	10,239	9,676	17,160
Operating expense					
Goods for Resale	-1,421	-1,786	-2,157	-2,034	-2,516
Operating expense	-2,259	-2,122	-4,915	-4,176	-10,462
Personnel expense	-8,310	-4,453	-12,768	-8,561	-16,245
Depreciation and amortization of tangible and intangible assets	-1,155	-1,155	-2,309	-2,308	-4,617
Other operating expenses	-221	-256	-567	-317	-734
	-13,366	-9,772	-22,716	-17,396	-34,574
Operating profit (loss)	-7,390	-3,667	-12,477	-7,720	-17,414
Result from financial investments					
Other Interest income and similar items	333	573	880	583	1,912
Interest expenses and similar items	-505	-221	-861	-345	-2,120
	-172	352	19	238	-208
Profit after financial items	-7,562	-3,315	-12,458	-7,482	-17,622
Profit before tax	-7,562	-3,315	-12,458	-7,482	-17,622
Tax on profit for the period	0	0	0	0	0
Results for the Period	-7,562	-3,315	-12,458	-7,482	-17,622

Balance Sheet- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2024-06-30	2023-06-30	2023-12-31
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	288	4,840	2,564
	288	4,840	2,564
Tangible assets			
Equipment, tools and installations	38	49	44
Other machinery and other technical facilities	29	45	37
Leasing machines	3	41	22
	70	135	103
Financial assets			
Participations in group companies	66,198	66,198	66,198
Receivable from group companies	8,754	8,952	8,284
Other long term receivables	527	292	409
	75,479	75,442	74,891
Total Fixed Assets	75,837	80,417	77,558
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	3,690	2,211	3,265
	3,690	2,211	3,265
Current Receivables			
Accounts Receivable	899	857	549
Receivables from group companies	1,265	1,962	1,376
Current Tax Assets	0	0	0
Other Current Receivables	555	461	332
Prepaid expenses and accrued income	813	855	893
	3,532	4,135	3,150
Cash and Bank Balances	2,693	1,780	899
Total Current Assets	9,915	8,126	7,314
Total Assets	85,752	88,543	84,872

Balance Sheet- Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2024-06-30	2023-06-30	2023-12-31
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	8,054	7,047	7,047
Unregistered share capital	0	0	0
Fund for development expenses	288	4,840	2,564
	8,342	11,887	9,611
Non-restricted equity			
Share premium reserves	264,125	246,550	246,550
Other non-restricted equity	-189,469	-176,399	-174,123
Results for the period	-12,458	-7,482	-17,622
	62,198	62,669	54,805
Total Equity	70,540	74,556	64,416
Provisions			
Other provisions for pensions and similar obligations	527	292	409
Other provisions	3,684	0	0
	4,211	292	409
Long Term Liabilities			
Other long term liabilities	2,014	0	2,848
Total Long Term Liabilities	2,014	0	2,848
Current Liabilities			
Liabilities to credit institutions	1,736	0	1,805
Accounts payable	1,163	650	849
Current payable to group company	864	5,960	4,588
Other current liabilities	1,431	2,243	6,110
Accrued expenses and deferred income	3,793	4,842	3,847
Total current liabilities	8,987	13,695	17,199
Total liabilities	8,987	13,695	17,199
Total Equity and Liabilities	85,752	88,543	84,872

Financial calendar

21 Nov 2024	Q3 Report
20 Feb 2025	2024 Year End Report
22 May 2025	Q1 Report
21 Aug 2025	Q2 Report
20 Nov 2025	Q3 Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se